1. World Health Organisation. Global tuberculosis report. Geneva, Switzerland: Licence CC BY- NC-SA 3.0 IGO; 2018.
2. Singh S, Mariappan TT, Shankar R, Sarda N, Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm. 2001;228:5–17.
3. World Health Organization. WHO guidelines on tuberculosis infection prevention and control 2019 update. Geneva, Switzerland: CC BY-NC-SA 3.0 IGO; 2019.
4. World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva, Switzerland: Licence: CC BY-NC-SA 3.0 IGO; 2017.
5. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ. 2001;79:61–8.